For the Quarter Ending September 2025
North America
• In United States, the Rabeprazole Price Index remained stable quarter-over-quarter in Q3 2025, despite rising input costs.
• Rabeprazole production costs increased in Q3 2025, driven by a 2.6% year-over-year PPI rise in August 2025.
• Demand for Rabeprazole was supported by a 5.42% year-over-year increase in retail sales in September 2025.
• The Rabeprazole Price Forecast faces pressure from an overall uptick in natural gas prices year-over-year in Q3 2025.
• Overall chemical manufacturing activity contracted in Q3 2025, impacting Rabeprazole supply.
• US national health expenditures grew in 2025, strengthening the broader healthcare sector for Rabeprazole demand.
• A 4.3% unemployment rate in September 2025 supported Rabeprazole demand by enhancing patient access and affordability.
• Inflationary pressures, with CPI up 3.0% year-over-year in September 2025, impacted overall production expenses.
• Raw material inventory levels for chemical manufacturers contracted or remained stable in Q3 2025.
Why did the price of Rabeprazole change in September 2025 in North America?
• Rising production costs, influenced by a 2.6% year-over-year PPI increase in August 2025, pressured prices.
• Strong consumer spending, with retail sales up 5.42% year-over-year in September 2025, supported demand.
• Contracting chemical manufacturing activity in Q3 2025, alongside stable inventories, influenced supply.
APAC
• In China, the Rabeprazole Price Index declined quarter-over-quarter in Q3 2025, influenced by deflationary pressures.
• Rabeprazole production costs fell in Q3 2025, as producer prices declined 2.3% year-on-year in September 2025.
• Demand for Rabeprazole was supported by robust pharmaceutical market expansion and 6.5% industrial production growth in September 2025.
• The Rabeprazole Price Index faced downward pressure in Q3 2025, reflecting 0.3% consumer price deflation in September 2025.
• China's pharmaceutical market experienced robust expansion in Q3 2025, driven by an aging population and chronic diseases.
• Global oil inventories rose in Q3 2025, contributing to downward pressure on crude oil prices, impacting energy costs.
• The Manufacturing Index indicated a contracting sector in September 2025, suggesting a broader economic slowdown.
• Government initiatives bolstered pharmaceutical innovation and high-end biopharma production in China during Q3 2025.
Why did the price of Rabeprazole change in September 2025 in APAC?
• Deflationary pressures, with CPI falling 0.3% year-on-year in September 2025, exerted downward pressure.
• Producer prices declined 2.3% year-on-year in September 2025, reducing raw material and manufacturing costs.
• A contracting Manufacturing Index in September 2025 signaled weak industrial demand, impacting overall pricing.
Europe
• In Germany, the Rabeprazole Price Index remained stable in Q3 2025, reflecting mixed macroeconomic pressures.
• Rabeprazole production costs eased in Q3 2025 due to declining benzene, methanol, and naphtha feedstock prices.
• Demand for pharmaceutical products, including Rabeprazole, strengthened in Q3 2025, driven by an aging population.
• Producer prices decreased by 1.7% year-over-year in September 2025, lowering Rabeprazole manufacturing input costs.
• Consumer confidence declined significantly to -23.6 in September 2025, impacting OTC Rabeprazole demand.
• High energy costs and 2.4% CPI in September 2025 pressured Rabeprazole operating expenses.
• Industrial production contracted by 1.0% year-over-year in September 2025, affecting overall healthcare budgets.
• Retail sales grew modestly by 0.8% year-over-year in September 2025, while unemployment was 3.9%.
• Ample chemical inventories and increased pharmaceutical imports in Q3 2025 intensified market competition.
Why did the price of Rabeprazole change in September 2025 in Europe?
• Producer prices decreased by 1.7% year-over-year in September 2025, reducing Rabeprazole input costs.
• High energy costs and 2.4% CPI in September 2025 pressured Rabeprazole operating expenses.
• Increased pharmaceutical imports and ample inventories in Q3 2025 intensified market competition.
For the Quarter Ending December 2022
North America
The fourth quarter of 2022 saw a significant drop in Rabeprazole API prices in North America, with CFR Los Angeles values falling by 5.8% from $108500/mt to $102150/mt from October to December. Due to a one-week holiday in China, a prominent exporter, imports of Rabeprazole were delayed the first week of October.
Despite this, the US's downward pricing trend was sustained by the substantial stocks retained by domestic retailers and the low demand for Rabeprazole. The damaged supply chain did, however, begin to mend as the economy grew, and the port backlog significantly shrank in the second half of Q4.
Asia Pacific
During the fourth quarter of 2022, the price of Rabeprazole across the Asia Pacific region displayed a downward price trajectory. Between October and December, FOB Shanghai prices in China decreased from $88750/mt to $84250/mt. The first week of October saw a modest decline in Rabeprazole orders for China's API market due to the shutdown of production facilities for the Golden Week. After a one-week holiday and the market's reopening, domestic traders faced several conflicting signals that made it challenging for the players to keep up with the slow development seen in some downstream industries. Additionally, the weak demand for Rabeprazole kept the market moving downward. Government authorities altered their zero-covid restrictions in response to criticism and intense unhappiness in the nation, rendering it vulnerable in the second half of the fourth quarter of 2022.
Europe
The German market for Rabeprazole mimicked the same trend as that of North America and Asia. The CFR Hamburg prices were settled at $112000/mt and $108500/mt in October and December, respectively, demonstrating a downtrend. Offtakes were higher in the first half of the quarter than they were in December due to the unexpected increase in coronavirus infections, which led to a decline in international demand during the latter weeks of December. However, factors like COVID incidents and the conflict between Russia and Ukraine continued to have a negative impact on the economy as a whole. Germany's CPI also decreased at the conclusion of the year, along with the ease in supply chain issues.
For the Quarter Ending September 2022
North America
During the third quarter of 2022, the Rabeprazole API market witnessed an upsurged pricing sentiment in the North American region. The market enhanced during the first half of Q3 2022 due to a stable increment in its downstream demand. Prices rose significantly following the mid of Q3 owing to the tightened supply and port congestion leading to the shortage of consignments. Furthermore, in terms of demand, the domestic merchants were left with fewer stocks which were insufficient to meet the rolled-up demand. With the termination of the third quarter, the prices shadowed a similar trend and were demonstrated at USD 106850/MT CFR Los Angeles.
Asia Pacific
In APAC Region, the values of Rabeprazole witnessed an incremented state throughout the third quarter on the back of continual increased downstream demand. With the onset of Q3 2022, the ease in trading momentum from China positively supported Rabeprazole's price trend. Towards the end of the third quarter's first half, Rabeprazole values inclined stably with the demand side balanced by the supply side. Moreover, the manufacturing process was relieved owing to slight ease in the COVID-19 pandemic, which further kept the market sentiments of Rabeprazole on the positive side. With this, the prices recorded for Rabeprazole in the Chinese market were settled at USD 87280/MT FOB Shanghai.
Europe
In the Europe Region, Rabeprazole API prices inclined during the third quarter of 2022. The market surged significantly in the first half of Q3 owing to the geopolitical conflicts between the Russia-Ukraine, during which the trade routes showed signs of congestion following a tense trade atmosphere in the region. Further, the increased demand and insufficient supplies with the domestic retailers propelled them to raise their stocks to meet the demand side, which in turn also positively supported Rabeprazole's price trends in Europe. With this towards the termination of Q3, the prices got settled at USD 110650/ MT CFR Hamburg with stabled inclination.
For the Quarter Ending June 2022
North America
The North American region showcased a bearish price sentiment for Rabeprazole sodium API in the market during the second quarter of 2022. In the market, the price of the upstream derivative timoprazole dropped down, which caused the price of the rabeprazole sodium API to be reduced. Downstream demand decreases, resulting in lower customer interest and higher dealer inventory levels. There were sufficient stocks with the traders in the market that could further fulfill the overall local demand. Lower fuel prices due to lessened import and export activities decreased freight rates and accumulated shipments which collectively impacted the market and Rabeprazole sodium prices in the region overall.
Asia Pacific
In the APAC region, the market of Rabeprazole witnessed a downward trend in its prices during the Second Quarter of 2022, backed by reduced downstream demand from various end-user enterprises, resulting in stockpiled inventories with the suppliers in the market. The prices for upstream derivatives also went down, negatively affecting the Rabeprazole market. Further, India being the major exporter of Rabeprazole to various regions, reduced necessity resulted in lessened trading activities, leading to lesser freight charges, thereby affecting the overall cost of Rabeprazole in the areas. Whereas the market was stable at the start of the second quarter, the prices dropped down significantly towards the termination of the second quarter. The prices recorded for Rabeprazole were settled at INR 5050000/MT Ex-Mumbai.
Europe
During the Second Quarter, the prices for Rabeprazole observed bearish price trends in the European market backed by reduced trading activities due to the Russian invasion of Ukraine, which resulted in rerouting events and delayed shipment from various regions, majorly India being the major exporter of Rabeprazole API. The reduction in downstream demand from various pharmaceutical and biopharmaceutical industries negatively affected the cost of Rabeprazole API in the market. Further, reduced upstream derivative prices results in lowered downstream Rabeprazole API prices in the market. Manufacturers were forced to reduce the prices to manage the steady offtake of downstream API-based products in the domestic market.
